Teva Pharmaceuticals

Name

Teva Pharmaceuticals

Legal name

Teva Pharmaceutical Industries Ltd.

Website

https://tevapharm.com

Company type

Public

Founded year

1906

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

Teva Pharmaceutical Industries is an Israeli-headquartered, NYSE-listed biopharmaceutical company with ~37,000 employees across 57 markets, developing branded innovative medicines (AUSTEDO, AJOVY, UZEDY), generics, and biosimilars for ~200 million patients daily under its Pivot to Growth strategy.

Ownership category

akta.pro rank

Product category

Pharmaceuticals

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Specialty Care Pharmaceuticals (HLAIAAAB)

akta.pro secondary industries

Primary Care & General Medicine Pharmaceuticals (HLAIAAAA), Small-Molecule Generics (Branded/Unbranded) (HLAIABAA), Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)

Keywords

• Generic pharmaceuticals
• Innovative biopharmaceuticals
• Biosimilar medicines
• Long-acting injectables
• Drug delivery platforms

Headquarters

HQ city

Tel Aviv

HQ country

Israel

HQ region

Middle East

Offices6 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Supply Chain, Personnel, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Branded innovative pharmaceutical product sales: Recurring revenue from sales of Teva's proprietary innovative brands led by Austedo/Austedo XR (tardive dyskinesia, Huntington's disease chorea), Ajovy (migraine), and Uzedy (schizophrenia/Bipolar I long-acting injectable). Q1 2026 innovative portfolio generated ~$838M (up 41% YoY), surpassing U.S. generics for the first time.
2. Generic medicines sales: High-volume, lower-margin sales of generic small molecules; Teva's generics portfolio contributed $36.4 billion in healthcare system savings across 21 countries. Generics remained a meaningful but declining share of revenue in Q1 2026 (-16% YoY) as Teva pivots toward branded innovative medicines.
3. Biosimilar product sales: Revenue from commercialization of biosimilars including AHZANTIVE (aflibercept biosimilar to Eylea) launched across France, Germany, Spain, the Netherlands (May/June 2026) and other biosimilars in pipeline via partnerships with Alvotech and Samsung Bioepis.
4. Royalty and licensing income: Royalty and licensing revenue from collaboration and co-funding deals, including the Royalty Pharma up-to-$125M funding agreement for olanzapine LAI (TEV-'749) and the Blackstone Life Sciences $400M milestone-based funding for duvakitug, generating low single-digit royalties on worldwide sales. Mid-to-high single-digit royalties received by Medincell on Uzedy net sales illustrate the model.

Go-to-market motion4 records

Distribution channels4 records

Core offering

Teva Pharmaceutical Industries Ltd. develops, manufactures, and commercializes a portfolio of innovative branded pharmaceuticals, generic medicines, and biosimilars across neuroscience, immunology, and other therapeutic areas. Its innovative brands include AUSTEDO/AUSTEDO XR (deutetrabenazine for tardive dyskinesia/Huntington's disease), AJOVY (fremanezumab for migraine), UZEDY (risperidone long-acting injectable for schizophrenia), alongside late-stage assets olanzapine LAI (TEV-'749), duvakitug, and ecopipam, while its generics franchise delivers affordable small molecules globally and its biosimilars portfolio includes AHZANTIVE (aflibercept), PONLIMSI (denosumab), and partner-developed candidates.

Product overview

Teva Pharmaceuticals operates as an integrated pharmaceutical platform combining an innovative biopharmaceutical business with a world-class generics and biosimilars foundation. The innovative medicines portfolio centers on branded growth engines across neuroscience (AUSTEDO/AUSTEDO XR for tardive dyskinesia and Huntington's disease, AJOVY for migraine, UZEDY for schizophrenia, and the late-stage olanzapine LAI / TEV-'749 and ecopipam pipeline) and immunology (duvakitug/TEV-48574 for inflammatory bowel disease, co-developed with Sanofi). Teva is simultaneously scaling its biosimilars business (AHZANTIVE/aflibercept, PONLIMSI/denosumab, partnered candidates AVT16, AVT05, AVT06 with Alvotech, and Soliris/EPYSQLI biosimilars with Samsung Bioepis) and leveraging its global generics portfolio to deliver $36.4 billion in healthcare system savings across 21 countries. The platform is enabled by advanced manufacturing, AI-driven R&D, and a global commercial execution infrastructure built on Veeva Vault CRM across approximately 37,000 employees operating in 57 markets.

Differentiator

Problem solved

Functional benefit

Brands

• AUSTEDO: Deutetrabenazine tablets and AUSTEDO XR extended-release tablets for tardive dyskinesia and Huntington's disease chorea. Key branded franchise targeting more than $3 billion in peak sales.
• UZEDY
• AJOVY
• AHZANTIVE
• Ecopipam (TEV-'749)
• Copaxone
• Duvakitug (TEV-48574)

Products and services

• AUSTEDO / AUSTEDO XR (deutetrabenazine) VMAT2 inhibitor approved for tardive dyskinesia and Huntington's disease chorea in adults, available as AUSTEDO XR once-daily extended-release tablets. Teva's leading branded growth engine targeting over $3 billion in peak sales.
• AJOVY (fremanezumab) Monoclonal antibody targeting CGRP for the preventive treatment of migraine in adults; part of Teva's innovative neuroscience franchise with Q1 2026 sales of $196 million (up 35% YoY).
• UZEDY (risperidone long-acting injectable) FDA-approved long-acting injectable risperidone for schizophrenia and Bipolar I Disorder, developed using Teva/Medincell technology. Q1 2026 net sales reached $63 million, up 62% year-over-year.
• AHZANTIVE (aflibercept biosimilar) Biosimilar to Eylea (aflibercept) for treating wet AMD, DME, CNV, and RVO; launched in Europe across France, Germany, Spain, and the Netherlands in May/June 2026.
• PONLIMSI (denosumab biosimilar) Denosumab biosimilar approved by the FDA in March 2026, expanding Teva's biosimilars portfolio.
• Copaxone (glatiramer acetate) Teva's legacy multiple sclerosis treatment referenced as one of the company's registered trademarks; a long-established specialty pharmaceutical product.
• QVAR / QVAR RediHaler (beclomethasone dipropionate) Inhaled corticosteroid metered-dose inhaler for asthma treatment, marketed under the QVAR and QVAR RediHaler brands.
• Generic Medicines portfolio Teva's world-class generics business delivering affordable medicines at scale across global markets, including generic metformin, generic liraglutide (FDA-approved August 2025), and others contributing $36.4 billion in healthcare system savings across 21 countries.
• Teva Biosimilar Medicines Expanding biosimilars portfolio including marketed AHZANTIVE (aflibercept), PONLIMSI (denosumab), and pipeline biosimilars developed with partners Alvotech and Samsung Bioepis.
• Consumer Healthcare Consumer-focused healthcare offerings complementing Teva's innovative and generics businesses as part of its diversified pharmaceutical portfolio.

Quantifiable outcome

• Q1 2026 innovative brands generated ~$838M in revenue, up 41% year-over-year, surpassing U.S. generics portfolio ($612M) for the first time
• +7 more outcomes

Named customers3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration1 record

AI capability3 records

Feature4 records

Partnerships

Nine partnerships are on record, tiered flagship, moderate and major.

• Emalex Biosciences (acquired by Teva)flagshipStrategic or Co-development Partner · 10 June 2026Acquisition closed June 10, 2026; Teva paid $700M upfront plus up to $200M in commercial milestone payments and royalties for ecopipam, a first-in-class selective dopamine D1 receptor antagonist for pediatric Tourette syndrome. NDA submission anticipated H2 2026. Acquired as part of Pivot to Growth strategy.
• Paragon Biosciences (parent of Emalex Biosciences at sale)moderateStrategic or Co-development Partner · 10 June 2026Paragon Biosciences sold its founded company Emalex Biosciences to Teva Pharmaceutical in a $700 million cash deal, with additional milestone payments and royalties. The transaction demonstrates Paragon's biotech incubation model and supports ecopipam's path to regulatory submission.
• AlvotechflagshipStrategic or Co-development Partner · 4 June 2026Alvotech develops and manufactures biosimilars (AVT05 - Simponi/Simponi Aria biosimilar; AVT06 - Eylea biosimilar; AVT16 - Entyvio interchangeable biosimilar) while Teva handles U.S. commercialization. FDA accepted BLAs for AVT16 and accepted resubmissions for AVT05/AVT06, with six-month reviews underway. Alvotech targets five products on the U.S. market by year-end.
• Klinge Biopharma GmbH and Formycon AGmajorChannel Partner/ Reseller/ Distributor · 4 June 2026Semi-exclusive commercialization agreement for AHZANTIVE (aflibercept biosimilar to Eylea) in Europe, launched in France, Germany, Spain, and the Netherlands in May/June 2026 with additional markets planned. AHZANTIVE received European Commission approval in 2025 for treating wet AMD, DME, CNV, and RVO.
• Veeva SystemsflagshipTechnology or Integration · 27 May 2026Teva Pharmaceuticals has committed to implementing Veeva Vault CRM globally as part of an expanded strategic partnership. The Vault CRM platform serves as the technical foundation for Teva's commercial execution across neuroscience, immunology, generics, biosimilars, and pharmacy brands, including features like Agentic Call Report that generate compliant Commercial Evidence. Veeva serves over 1,500 customers in life sciences.
• SanofiflagshipStrategic or Co-development Partner · 1 January 202650/50 co-development partnership on duvakitug (TEV-48574), a TL1A-targeting monoclonal antibody for ulcerative colitis and Crohn's disease. Phase 2b results showed 58% clinical remission in ulcerative colitis and 55% endoscopic response in Crohn's disease; Phase 3 results for duvakitug expected in late 2028/Q1 2029.
• Samsung BioepismajorStrategic or Co-development Partner · 1 January 2025Partnership to develop and commercialize biosimilar versions of Soliris and EPYSQLI for paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) patients in the United States.
• Jiangsu Nhwa PharmaceuticalmajorChannel Partner/ Reseller/ Distributor · 1 February 2024Distribution partnership to commercialize AUSTEDO in China, leveraging Jiangsu Nhwa's neuropsychiatric market presence. Supports geographic expansion of Teva's deutetrabenazine franchise.
• MedincellflagshipStrategic or Co-development Partner · 13 November 2023Strategic collaboration to accelerate development of olanzapine LAI (TEV-'749) for schizophrenia using Medincell's SteadyTeq copolymer technology. The European Medicines Agency accepted the Marketing Authorization Application in May 2026, supported by Phase 3 SOLARIS study data. Teva pays Medincell mid- to high-single-digit royalties on Uzedy net sales plus up to $105M in commercial milestone payments; additional AbbVie collaboration also referenced.

Scale indicators14 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Sandoz: Sandoz is the most directly comparable peer to Teva, operating as a global leader in generics and biosimilars spun out of Novartis in 2023. Like Teva, Sandoz competes in small-molecule generics, biosimilars, and selected branded specialty categories across the same geographic markets, with similar customer bases of payers, wholesalers, and pharmacy chains.
• Viatris: Viatris was formed from the merger of Mylan and Upjohn (Pfizer's established brands business), making it a direct competitor to Teva in off-patent generics, complex generics, and select specialty branded categories. Both companies serve similar payer and pharmacy customers globally and are pursuing similar pivots toward higher-margin specialty and biosimilar portfolios.
• Neurocrine Biosciences: Neurocrine is the most direct competitive threat in Teva's lead growth engine, with Ingrezza (valbenazine) competing head-to-head against Austedo in the tardive dyskinesia market. Both companies compete for the same neurology prescribers and specialty pharmacy channels, making Neurocrine the cleanest comparable for Teva's branded neurology franchise.
• Sun Pharmaceutical Industries: Sun Pharma is one of the world's largest specialty generics manufacturers, with overlapping product portfolios in complex generics and biosimilars and a similar global commercial footprint including U.S., European, and emerging market operations. Sun's specialty branded business (e.g., Tildrakizumab/Ilumya) parallels Teva's effort to grow branded innovative revenue atop a generics base.
• Dr. Reddy's Laboratories: Dr. Reddy's is a major India-based generics manufacturer with comparable U.S. and European generic footprint, biosimilar ambitions, and an emerging specialty branded business. The companies compete directly in U.S. retail and institutional generic channels and increasingly in biosimilars.
• Lupin Pharmaceuticals: Lupin is a global generics manufacturer with significant U.S. and European presence, competing with Teva in complex generics, biosimilars, and specialty branded categories. Its scale and therapeutic area overlap make it a useful comparable for evaluating Teva's generics-to-specialty transition.

Emerging players

• Alvotech: Alvotech is both Teva's biosimilar development partner (AVT05, AVT06, AVT16) and an emerging biosimilars competitor pursuing its own commercial strategy. Their overlapping biosimilar pipelines targeting immunology and ophthalmology indications make Alvotech a directly relevant peer for evaluating Teva's biosimilar growth opportunity.

Broad incumbents

• Sanofi: Sanofi is Teva's 50/50 co-development partner on duvakitug for ulcerative colitis and Crohn's disease, and operates as a broad incumbent in immunology (Dupixent) and migraine that overlaps with Teva's innovative therapeutic focus. Sanofi's immunology franchise provides a benchmark for Teva's pipeline ambition in IBD.
• Organon & Co. Organon was spun off from Merck to focus on women's health and established brands, and pursues a similar 'innovative + generics-adjacent' hybrid model. While its therapeutic focus is narrower than Teva's, both companies share a transition narrative from commodity generics toward higher-margin specialty categories.
• AbbVie: AbbVie is a broader incumbent biopharmaceutical player with neuroscience (Vraylar for schizophrenia/bipolar) and immunology (Skyrizi, Rinvoq, Humira) franchises that directly overlap Teva's targeted therapeutic areas. AbbVie's commercial scale and pipeline depth in these areas provide an aspirational comparable for Teva's Pivot to Growth ambition.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/tevapharm
• Facebookfacebook.com/tevapharm
• LinkedInlinkedin.com/company/teva-pharmaceuticals

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles20 records

Subsidiaries3 records

Funding overview

Funding rounds6 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A13 records

Investments11 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Teva Pharmaceuticals